Spire Wealth Management’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-215
Closed -$163K – 2745
2021
Q4
$163K Buy
215
+211
+5,275% +$169K ﹤0.01% 1182
2021
Q3
$4K Buy
+4
New +$2.59K ﹤0.01% 2349
2021
Q2
– Sell
-351
Closed -$292K – 2826
2021
Q1
$292K Hold
351
– – 0.01% 880

Other funds holding MTNB

Spire Wealth Management's MTNB Position: Q1 2022 in Review

Spire Wealth Management sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 215 shares — an estimated $163K sold.

Spire Wealth Management first reported a position in MTNB in Q1 2021 and held it in 3 quarters. The position peaked at $292K in Q1 2021. 54 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

  • Spire Wealth Management reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 215 Matinas BioPharma shares in Q1 2022, an estimated $163K.
  • Spire Wealth Management first reported a position in Matinas BioPharma in Q1 2021 and held it in 3 quarters.
  • Spire Wealth Management's Matinas BioPharma position peaked at $292K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.